EVLA and Optimal Timing of Sclerotherapy
Launched by TURKU UNIVERSITY HOSPITAL · Feb 24, 2021
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "EVLA and Optimal Timing of Sclerotherapy," is looking to find the best timing for a treatment called sclerotherapy in patients who have had a procedure called Endovenous Laser Ablation (EVLA) for varicose veins. Varicose veins are swollen and twisted veins that can cause discomfort and other symptoms in the legs. The study will help determine when sclerotherapy, which involves injecting a solution into the veins to close them off, works best after EVLA.
To be eligible for this trial, participants need to be at least 18 years old and have varicose veins in their legs that are causing specific symptoms. They should not have serious health problems or a history of blood clots. If you or someone you know is interested in participating, the trial is not yet recruiting, but it will involve monitoring and receiving treatments related to your varicose vein condition. This study aims to improve treatment options for people dealing with similar issues.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Varicose disease of lower extremity caused by reflux of VSM, SSV or AASV to be treated with EVLA. Age over 18 years. Clinical symptoms C2-3.
- Exclusion Criteria:
- • No severe comorbidities. Previous DVT.
About Turku University Hospital
Turku University Hospital (TYKS) is a leading academic medical center located in Turku, Finland, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a key institution within the University of Turku, TYKS integrates cutting-edge medical education with state-of-the-art clinical services, offering a broad spectrum of specialized care. The hospital actively participates in clinical trials, facilitating the translation of scientific discoveries into practical treatments, and enhancing patient outcomes. With a multidisciplinary approach and a focus on collaboration, TYKS aims to contribute significantly to the global medical community through its rigorous research initiatives and commitment to patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Turku, , Finland
Patients applied
Trial Officials
Harri Hakovirta, Professor
Study Chair
University of Turku
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials